Modality
Nanobody
MOA
MDM2i
Target
CD123
Pathway
Innate Imm
MCL
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
~Dec 2023
→ ~Mar 2025
Phase 3
Jun 2025
→ Aug 2025
Phase 3Current
NCT07566593
2,665 pts·MCL
2025-06→2025-08·Recruiting
2,665 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-08-148mo agoPh3 Readout· MCL
Trial Timeline
Q3
P3
Recruit…
Catalysts
Ph3 Readout
2025-08-14 · 8mo ago
MCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07566593 | Phase 3 | MCL | Recruiting | 2665 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 |